Blueprint Medicines Corp. (NASDAQ:BPMC) posted its quarterly earnings data on Thursday. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.17. The business earned $6.16 million during the quarter, compared to analysts’ expectations of $6.06 million. Blueprint Medicines Corp. had a negative net margin of 284.85% and a negative return on equity of 46.01%. The business’s revenue was up 79.6% on a year-over-year basis. During the same period last year, the firm posted ($0.47) earnings per share.

Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) opened at 33.19 on Friday. The company has a 50 day moving average of $29.53 and a 200 day moving average of $23.45. The stock’s market cap is $905.49 billion. Blueprint Medicines Corp. has a 12 month low of $13.04 and a 12 month high of $34.47.

Earnings History for Blueprint Medicines Corp. (NASDAQ:BPMC)

BPMC has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Blueprint Medicines Corp. from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a report on Thursday, August 11th. Cowen and Company reiterated a “buy” rating on shares of Blueprint Medicines Corp. in a report on Tuesday, August 9th. Canaccord Genuity initiated coverage on shares of Blueprint Medicines Corp. in a report on Friday, August 5th. They issued a “buy” rating and a $26.00 price objective for the company. TheStreet raised shares of Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a research note on Friday, July 29th. Finally, Wedbush reissued an “outperform” rating and set a $41.00 target price on shares of Blueprint Medicines Corp. in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $30.00.

In related news, Director Daniel Lynch sold 21,800 shares of Blueprint Medicines Corp. stock in a transaction dated Thursday, October 13th. The shares were sold at an average price of $30.02, for a total transaction of $654,436.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.93% of the company’s stock.

A number of institutional investors have recently made changes to their positions in BPMC. BlackRock Group LTD boosted its stake in Blueprint Medicines Corp. by 160.8% in the second quarter. BlackRock Group LTD now owns 6,992 shares of the company’s stock valued at $141,000 after buying an additional 4,311 shares during the last quarter. BlackRock Advisors LLC boosted its stake in Blueprint Medicines Corp. by 96.1% in the second quarter. BlackRock Advisors LLC now owns 8,245 shares of the company’s stock valued at $167,000 after buying an additional 4,040 shares during the last quarter. American International Group Inc. boosted its stake in Blueprint Medicines Corp. by 110.0% in the second quarter. American International Group Inc. now owns 11,520 shares of the company’s stock valued at $233,000 after buying an additional 6,034 shares during the last quarter. Nationwide Fund Advisors boosted its stake in Blueprint Medicines Corp. by 114.0% in the second quarter. Nationwide Fund Advisors now owns 12,969 shares of the company’s stock valued at $263,000 after buying an additional 6,909 shares during the last quarter. Finally, Dumont & Blake Investment Advisors LLC bought a new stake in Blueprint Medicines Corp. during the third quarter valued at $267,000. 73.57% of the stock is owned by hedge funds and other institutional investors.

About Blueprint Medicines Corp.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

5 Day Chart for NASDAQ:BPMC

Receive News & Stock Ratings for Blueprint Medicines Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corp. and related stocks with our FREE daily email newsletter.